{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T13:20:51Z","timestamp":1790601651051,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,1,17]],"date-time":"2021-01-17T00:00:00Z","timestamp":1610841600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,17]],"date-time":"2021-01-17T00:00:00Z","timestamp":1610841600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Human Cell"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s13577-020-00471-2","type":"journal-article","created":{"date-parts":[[2021,1,17]],"date-time":"2021-01-17T04:04:30Z","timestamp":1610856270000},"page":"644-653","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["High-resolution melting effectively pre-screens for TP53 mutations before direct sequencing in patients with diffuse glioma"],"prefix":"10.1007","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4242-0623","authenticated-orcid":false,"given":"Kiyotaka","family":"Saito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyotaka","family":"Yokogami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunari","family":"Maekawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichiro","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumitaka","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asako","family":"Mizuguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Takeshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,17]]},"reference":[{"issue":"7","key":"471_CR1","doi-asserted-by":"publisher","first-page":"301","DOI":"10.2176\/nmc.ra.2017-0010","volume":"57","author":"T Komori","year":"2017","unstructured":"Komori T. The 2016 WHO classification of tumours of the central nervous system: the major points of revision. Neurol Med Chir Tokyo. 2017;57(7):301\u201311. https:\/\/doi.org\/10.2176\/nmc.ra.2017-0010.","journal-title":"Neurol Med Chir Tokyo"},{"issue":"6","key":"471_CR2","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","volume":"131","author":"DN Louis","year":"2016","unstructured":"Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131(6):803\u201320. https:\/\/doi.org\/10.1007\/s00401-016-1545-1.","journal-title":"Acta Neuropathol"},{"key":"471_CR3","volume-title":"WHO classification of tumours of the central nervous system","author":"A Von Deimling","year":"2016","unstructured":"Von Deimling A, Perry A, Louis D, Ohgaki H, Wiestler O, Cavenee W. WHO classification of tumours of the central nervous system. Lyon: IARC; 2016."},{"issue":"5","key":"471_CR4","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00381-018-3765-2","volume":"34","author":"E Cambruzzi","year":"2018","unstructured":"Cambruzzi E. Medulloblastoma, WNT-activated\/SHH-activated: clinical impact of molecular analysis and histogenetic evaluation. Childs Nerv Syst. 2018;34(5):809\u201315. https:\/\/doi.org\/10.1007\/s00381-018-3765-2.","journal-title":"Childs Nerv Syst"},{"issue":"40","key":"471_CR5","doi-asserted-by":"publisher","first-page":"64910","DOI":"10.18632\/oncotarget.11912","volume":"7","author":"B Murnyak","year":"2016","unstructured":"Murnyak B, Hortobagyi T. Immunohistochemical correlates of TP53 somatic mutations in cancer. Oncotarget. 2016;7(40):64910\u201320. https:\/\/doi.org\/10.18632\/oncotarget.11912.","journal-title":"Oncotarget"},{"issue":"9","key":"471_CR6","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/humu.23035","volume":"37","author":"L Bouaoun","year":"2016","unstructured":"Bouaoun L, Sonkin D, Ardin M, Hollstein M, Byrnes G, Zavadil J, et al. TP53 variations in human cancers: new lessons from the IARC TP53 database and genomics data. Hum Mutat. 2016;37(9):865\u201376. https:\/\/doi.org\/10.1002\/humu.23035.","journal-title":"Hum Mutat"},{"issue":"2","key":"471_CR7","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s12017-014-8290-1","volume":"16","author":"LE Salnikova","year":"2014","unstructured":"Salnikova LE. Clinicopathologic characteristics of brain tumors are associated with the presence and patterns of TP53 mutations: evidence from the IARC TP53 Database. Neuromol Med. 2014;16(2):431\u201347. https:\/\/doi.org\/10.1007\/s12017-014-8290-1.","journal-title":"Neuromol Med"},{"issue":"22","key":"471_CR8","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1056\/nejmc1610144","volume":"375","author":"AK Chan","year":"2016","unstructured":"Chan AK, Mao Y, Ng HK. TP53 and histone H3.3 mutations in triple-negative lower-grade gliomas. N Engl J Med. 2016;375(22):2206\u20138. https:\/\/doi.org\/10.1056\/nejmc1610144.","journal-title":"N Engl J Med"},{"key":"471_CR9","doi-asserted-by":"publisher","first-page":"39743","DOI":"10.1038\/srep39743","volume":"6","author":"E Nie","year":"2016","unstructured":"Nie E, Jin X, Wu W, Yu T, Zhou X, Zhi T, et al. BACH1 promotes temozolomide resistance in glioblastoma through antagonizing the function of p53. Sci Rep. 2016;6:39743. https:\/\/doi.org\/10.1038\/srep39743.","journal-title":"Sci Rep"},{"issue":"19","key":"471_CR10","doi-asserted-by":"publisher","first-page":"6892","DOI":"10.1158\/0008-5472.CAN-04-1337","volume":"64","author":"H Ohgaki","year":"2004","unstructured":"Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL, et al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. 2004;64(19):6892\u20139. https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-1337.","journal-title":"Cancer Res"},{"issue":"3","key":"471_CR11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/s10014-011-0029-1","volume":"28","author":"H Ohgaki","year":"2011","unstructured":"Ohgaki H, Kleihues P. Genetic profile of astrocytic and oligodendroglial gliomas. Brain Tumor Pathol. 2011;28(3):177\u201383. https:\/\/doi.org\/10.1007\/s10014-011-0029-1.","journal-title":"Brain Tumor Pathol"},{"issue":"1","key":"471_CR12","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s00401-004-0861-z","volume":"108","author":"Y Okamoto","year":"2004","unstructured":"Okamoto Y, Di Patre PL, Burkhard C, Horstmann S, Jourde B, Fahey M, et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol. 2004;108(1):49\u201356. https:\/\/doi.org\/10.1007\/s00401-004-0861-z.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"471_CR13","doi-asserted-by":"publisher","first-page":"334","DOI":"10.7868\/S0026898417020185","volume":"51","author":"PP Sarma","year":"2017","unstructured":"Sarma PP, Dutta D, Mirza Z, Saikia KK, Baishya BK. Point mutations in the DNA binding domain of p53 contribute to glioma progression and poor prognosis. Mol Biol Mosk. 2017;51(2):334\u201341. https:\/\/doi.org\/10.7868\/S0026898417020185.","journal-title":"Mol Biol Mosk"},{"issue":"5","key":"471_CR14","first-page":"1117","volume":"8","author":"A Peraud","year":"2002","unstructured":"Peraud A, Kreth FW, Wiestler OD, Kleihues P, Reulen HJ. Prognostic impact of TP53 mutations and P53 protein overexpression in supratentorial WHO grade II astrocytomas and oligoastrocytomas. Clin Cancer Res. 2002;8(5):1117\u201324.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"471_CR15","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1111\/j.1471-4159.2005.03583.x","volume":"96","author":"M Hermisson","year":"2006","unstructured":"Hermisson M, Klumpp A, Wick W, Wischhusen J, Nagel G, Roos W, et al. O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem. 2006;96(3):766\u201376. https:\/\/doi.org\/10.1111\/j.1471-4159.2005.03583.x.","journal-title":"J Neurochem"},{"issue":"4","key":"471_CR16","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1245\/s10434-013-3380-0","volume":"21","author":"X Wang","year":"2014","unstructured":"Wang X, Chen JX, Liu JP, You C, Liu YH, Mao Q. Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide. Ann Surg Oncol. 2014;21(4):1337\u201344. https:\/\/doi.org\/10.1245\/s10434-013-3380-0.","journal-title":"Ann Surg Oncol"},{"issue":"8","key":"471_CR17","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1007\/s10072-012-1257-9","volume":"34","author":"X Wang","year":"2013","unstructured":"Wang X, Chen JX, Liu YH, You C, Mao Q. Mutant TP53 enhances the resistance of glioblastoma cells to temozolomide by up-regulating O(6)-methylguanine DNA-methyltransferase. Neurol Sci. 2013;34(8):1421\u20138. https:\/\/doi.org\/10.1007\/s10072-012-1257-9.","journal-title":"Neurol Sci"},{"key":"471_CR18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.wneu.2016.07.079","volume":"95","author":"C Zhang","year":"2016","unstructured":"Zhang C, Wang X, Hao S, Su Z, Zhang P, Li Y, et al. Analysis of treatment tolerance and factors associated with overall survival in elderly patients with glioblastoma. World Neurosurg. 2016;95:77\u201384. https:\/\/doi.org\/10.1016\/j.wneu.2016.07.079.","journal-title":"World Neurosurg"},{"issue":"3","key":"471_CR19","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1111\/j.1750-3639.1993.tb00749.x","volume":"3","author":"EW Newcomb","year":"1993","unstructured":"Newcomb EW, Madonia WJ, Pisharody S, Lang FF, Koslow M, Miller DC. A correlative study of p53 protein alteration and p53 gene mutation in glioblastoma multiforme. Brain Pathol. 1993;3(3):229\u201335.","journal-title":"Brain Pathol"},{"issue":"3","key":"471_CR20","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/bpa.12173","volume":"25","author":"H Takami","year":"2015","unstructured":"Takami H, Yoshida A, Fukushima S, Arita H, Matsushita Y, Nakamura T, et al. Revisiting TP53 mutations and immunohistochemistry\u2013a comparative study in 157 diffuse gliomas. Brain Pathol. 2015;25(3):256\u201365. https:\/\/doi.org\/10.1111\/bpa.12173.","journal-title":"Brain Pathol"},{"key":"471_CR21","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/1471-2407-7-168","volume":"7","author":"M Krypuy","year":"2007","unstructured":"Krypuy M, Ahmed AA, Etemadmoghadam D, Hyland SJ, Australian Ovarian Cancer Study G, DeFazio A, et al. High resolution melting for mutation scanning of TP53 exons 5-8. BMC Cancer. 2007;7:168. https:\/\/doi.org\/10.1186\/1471-2407-7-168.","journal-title":"BMC Cancer"},{"issue":"4","key":"471_CR22","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1007\/s00401-018-1826-y","volume":"135","author":"DN Louis","year":"2018","unstructured":"Louis DN, Giannini C, Capper D, Paulus W, Figarella-Branger D, Lopes MB, et al. cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma\/anaplastic astrocytoma, IDH-mutant. Acta Neuropathol. 2018;135(4):639\u201342. https:\/\/doi.org\/10.1007\/s00401-018-1826-y.","journal-title":"Acta Neuropathol"},{"issue":"3","key":"471_CR23","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s00401-018-1808-0","volume":"135","author":"DN Louis","year":"2018","unstructured":"Louis DN, Wesseling P, Paulus W, Giannini C, Batchelor TT, Cairncross JG, et al. cIMPACT-NOW update 1: not otherwise specified (NOS) and not elsewhere classified (NEC). Acta Neuropathol. 2018;135(3):481\u20134. https:\/\/doi.org\/10.1007\/s00401-018-1808-0.","journal-title":"Acta Neuropathol"},{"issue":"8","key":"471_CR24","doi-asserted-by":"publisher","first-page":"e0160489","DOI":"10.1371\/journal.pone.0160489","volume":"11","author":"R Hatae","year":"2016","unstructured":"Hatae R, Hata N, Yoshimoto K, Kuga D, Akagi Y, Murata H, et al. Precise detection of IDH1\/2 and BRAF hotspot mutations in clinical glioma tissues by a differential calculus analysis of high-resolution melting data. PLoS ONE. 2016;11(8):e0160489. https:\/\/doi.org\/10.1371\/journal.pone.0160489.","journal-title":"PLoS ONE"},{"issue":"1","key":"471_CR25","doi-asserted-by":"publisher","first-page":"e14522","DOI":"10.1371\/journal.pone.0014522","volume":"6","author":"J Gonzalez-Bosquet","year":"2011","unstructured":"Gonzalez-Bosquet J, Calcei J, Wei JS, Garcia-Closas M, Sherman ME, Hewitt S, et al. Detection of somatic mutations by high-resolution DNA melting (HRM) analysis in multiple cancers. PLoS ONE. 2011;6(1):e14522. https:\/\/doi.org\/10.1371\/journal.pone.0014522.","journal-title":"PLoS ONE"},{"key":"471_CR26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2407-14-13","volume":"14","author":"MA Ihle","year":"2014","unstructured":"Ihle MA, Fassunke J, Konig K, Grunewald I, Schlaak M, Kreuzberg N, et al. Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations. BMC Cancer. 2014;14:13. https:\/\/doi.org\/10.1186\/1471-2407-14-13.","journal-title":"BMC Cancer"},{"key":"471_CR27","doi-asserted-by":"publisher","DOI":"10.1007\/s10014-018-0322-3","author":"K Yokogami","year":"2018","unstructured":"Yokogami K, Yamasaki K, Matsumoto F, Yamashita S, Saito K, Tacheva A, et al. Impact of PCR-based molecular analysis in daily diagnosis for the patient with gliomas. Brain Tumor Pathol. 2018. https:\/\/doi.org\/10.1007\/s10014-018-0322-3.","journal-title":"Brain Tumor Pathol"},{"issue":"1","key":"471_CR28","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/cdd.2017.180","volume":"25","author":"EH Baugh","year":"2018","unstructured":"Baugh EH, Ke H, Levine AJ, Bonneau RA, Chan CS. Why are there hotspot mutations in the TP53 gene in human cancers? Cell Death Differ. 2018;25(1):154\u201360. https:\/\/doi.org\/10.1038\/cdd.2017.180.","journal-title":"Cell Death Differ"},{"issue":"1","key":"471_CR29","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/humu.20114","volume":"25","author":"T Soussi","year":"2005","unstructured":"Soussi T, Kato S, Levy PP, Ishioka C. Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations. Hum Mutat. 2005;25(1):6\u201317. https:\/\/doi.org\/10.1002\/humu.20114.","journal-title":"Hum Mutat"},{"issue":"3","key":"471_CR30","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.ccr.2014.01.021","volume":"25","author":"PA Muller","year":"2014","unstructured":"Muller PA, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell. 2014;25(3):304\u201317. https:\/\/doi.org\/10.1016\/j.ccr.2014.01.021.","journal-title":"Cancer Cell"},{"key":"471_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10060166","author":"S Kogan","year":"2018","unstructured":"Kogan S, Carpizo DR. Zinc metallochaperones as mutant p53 reactivators: a new paradigm in cancer therapeutics. Cancers Basel. 2018. https:\/\/doi.org\/10.3390\/cancers10060166.","journal-title":"Cancers Basel"},{"issue":"22","key":"471_CR32","doi-asserted-by":"publisher","first-page":"4171","DOI":"10.1007\/s00018-017-2575-0","volume":"74","author":"D Zhao","year":"2017","unstructured":"Zhao D, Tahaney WM, Mazumdar A, Savage MI, Brown PH. Molecularly targeted therapies for p53-mutant cancers. Cell Mol Life Sci. 2017;74(22):4171\u201387. https:\/\/doi.org\/10.1007\/s00018-017-2575-0.","journal-title":"Cell Mol Life Sci"},{"issue":"6","key":"471_CR33","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1002\/humu.20919","volume":"30","author":"EA Tindall","year":"2009","unstructured":"Tindall EA, Petersen DC, Woodbridge P, Schipany K, Hayes VM. Assessing high-resolution melt curve analysis for accurate detection of gene variants in complex DNA fragments. Hum Mutat. 2009;30(6):876\u201383. https:\/\/doi.org\/10.1002\/humu.20919.","journal-title":"Hum Mutat"},{"issue":"3","key":"471_CR34","doi-asserted-by":"publisher","first-page":"182","DOI":"10.2144\/000113913","volume":"53","author":"CJ Davidson","year":"2012","unstructured":"Davidson CJ, Zeringer E, Champion KJ, Gauthier M-P, Wang F, Boonyaratanakornkit J, et al. Improving the limit of detection for Sanger sequencing: a comparison of methodologies for KRAS variant detection. Biotechniques. 2012;53(3):182\u20138. https:\/\/doi.org\/10.2144\/000113913.","journal-title":"Biotechniques"},{"issue":"1","key":"471_CR35","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1038\/s41467-019-10489-2","volume":"10","author":"Y Sharma","year":"2019","unstructured":"Sharma Y, Miladi M, Dukare S, Boulay K, Caudron-Herger M, Gross M, et al. A pan-cancer analysis of synonymous mutations. Nat Commun. 2019;10(1):2569. https:\/\/doi.org\/10.1038\/s41467-019-10489-2.","journal-title":"Nat Commun"},{"issue":"3","key":"471_CR36","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.bbrc.2005.03.157","volume":"331","author":"A Duensing","year":"2005","unstructured":"Duensing A, Duensing S. Guilt by association? p53 and the development of aneuploidy in cancer. Biochem Biophys Res Commun. 2005;331(3):694\u2013700. https:\/\/doi.org\/10.1016\/j.bbrc.2005.03.157.","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Human Cell"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-020-00471-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13577-020-00471-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-020-00471-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T13:06:52Z","timestamp":1613999212000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13577-020-00471-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,17]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["471"],"URL":"https:\/\/doi.org\/10.1007\/s13577-020-00471-2","relation":{},"ISSN":["1749-0774"],"issn-type":[{"value":"1749-0774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,17]]},"assertion":[{"value":"9 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors report no conflict of interest concerning the materials or methods used in this study or the findings reported in this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}